Meta-based association of the lipoprotein lipase gene S447X variant with hypertension and blood pressure variation

Abstract

Association of the lipoprotein lipase (LPL) gene S447X variant with hypertension has been investigated extensively, whereas the results are often irreproducible. We therefore conducted a meta-analysis to examine whether S447X variant was associated with hypertension and blood pressure variation. Case-control reports published in English language and humans were identified from MEDLINE, EMBASE and Web of Science search engines as of 10 December 2009. Fixed-effects model was applied to pool data in the absence of between-studies heterogeneity, and random-effects model otherwise. A total of five studies (960 cases and 1145 controls) for hypertension and four studies (n=2777) for blood pressure were included. Compared with 447SS homogeneous carriers, those with 447X variant had a lower risk of hypertension (odds ratio (OR)=0.78; 95% confidence interval (CI): 0.62-0.98; P=0.03), and this effect reached significance under the fixed-effects model (I(2)=30% and P=0.22). Similarly, compared with 447S allele carriers, those with 447X allele carriers also had a lower risk of hypertension (OR=0.79; 95% CI: 0.64-0.98; P=0.03). In case of pregnancy-induced hypertension, no significance was observed (P>0.05). As for blood pressure association, there was no significant difference between 447X variant and 447SS homogeneous carriers for both systolic and diastolic blood pressure in the whole population, even stratified by gender (P>0.05). The Egger test told no publication bias for all associations. This meta-analysis demonstrated that LPL gene S447X variant was significantly associated with hypertension and showed no obvious relation with pregnancy-induced hypertension and blood pressure variation.

Association of Polymorphisms of Genes Involved in Lipid Metabolism with Blood Pressure and Lipid Values in Mexican Hypertensive Individuals

“…The mutated allele has also been associated with lower TG and SBP levels as well as higher HDL-C levels [ 33 ]. Consistent with such results, the presence of the p.474X allele has shown in previous reports a lower risk for developing coronary heart disease [ 33 ] and hypertension (OR 0.78; 95% CI: 0.62–0.98, P = 0.03) [ 34 ].…”

Searching for genes involved in hypertension development in special populations: children and pre-eclamptic women. Where are we standing now?

“…But, in a large cohort of white subjects, the LPL Asp9Asn mutation, LPL T-93G promoter mutation, and LPL Asn291Ser mutation were not associated with an increased risk for PE [186]. Moreover, despite the fact that a recently published meta-analysis showed that subjects carrying the 447X variant have a lower risk of primary hypertension (OR 0.79; 95% CI 0.64-0.98; p = 0.03), the same SNP was significantly associated neither with hypertension nor with BP variation during pregnancy [187].…”

Newborn LpL (Ser447Stop, Asn291Ser) genotypes and the interaction with maternal genotypes influence the risk for different types of preeclampsia: modulating effect on lipid profile and pregnancy outcome

“…Higher HDL-C and lower TG levels or a decreased risk for cardiovascular diseases in carriers of the Ser447Stop variant have been observed [23,24]. There are studies showing an association between this variant and preeclampsia [25,26]. Studies conducted by Wittrup et al [27]and Kim et al [16], but not Zhang et al [28] suggest a higher risk for cerebrovascular disease and preeclampsia in association with the Asn291Ser variant.…”